PRAX insider trading
HealthcarePraxis Precision Medicines, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Company website: praxismedicines.com
PRAX insider activity at a glance
FilingIQ has scored 194 insider transactions for PRAX since Oct 20, 2020. The most recent filing in our index is dated May 14, 2026.
Across the full history, 16 open-market purchases
and 29 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PRAX insider trades is 57.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PRAX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding PRAX
Frequently asked
- How many insider trades does FilingIQ track for PRAX?
- FilingIQ tracks 194 Form 4 insider transactions for PRAX (Praxis Precision Medicines, Inc.), covering filings from Oct 20, 2020 onwards. 5 of those were filed in the last 90 days.
- Are PRAX insiders net buyers or net sellers?
- Across the full Form 4 history for PRAX, 16 transactions (8%) were open-market purchases and 29 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PRAX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PRAX in?
- Praxis Precision Medicines, Inc. (PRAX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.89B.
Methodology & sources
Every PRAX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.